DE
CRL icon

DV Equities’s Charles River Laboratories CRL Stock Holding History

DV Equities’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$14K Buy
+70
New +$12.7K ﹤0.01% 596

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

DV Equities's CRL Position: Q4 2025 in Review

DV Equities opened a new position in Charles River Laboratories (CRL) in Q4 2025: 70 shares worth $14K. The stake represents ﹤0.01% of the portfolio and ranks #596 among its holdings.

583 funds tracked by Wall St. Rank hold CRL as of Q4 2025.

  • DV Equities held 70 shares of Charles River Laboratories worth $14K as of Q4 2025.
  • Charles River Laboratories was a new DV Equities position in Q4 2025.
  • Charles River Laboratories made up ﹤0.01% of DV Equities's portfolio in Q4 2025, its #596 holding.
  • 583 funds tracked by Wall St. Rank held Charles River Laboratories as of Q4 2025.

Based on DV Equities's 13F filing for Q4 2025, filed 17 Feb 2026.